Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy
Mathis Grossmann, Emma J Hamilton, Christopher Gilfillan, Damien Bolton, Daryl Lim Joon, Jeffrey D Zajac
Medical Journal of Australia | AUSTRALASIAN MED PUBL CO LTD | Published : 2011
This work was supported by an NHMRC Health Professional Fellowship to Mathis Grossmann, and research grants from Osteoporosis Australia, the Royal Australasian College of Physicians, the Austin Hospital Medical Research Foundation, and the Sir Edward Dunlop Medical Research Foundation.Mathis Grossmann is principal researcher of an investigator-initiated trial on the role of bisphosphonates in preventing micro-architectural decay in men with non-metastatic prostate cancer who are receiving androgen deprivation therapy, which is partially supported by Novartis Pharmaceuticals, and has received honoraria for educational lectures from AstraZeneca. Christopher Gilfillan is a member of an AstraZeneca prostate cancer advisory board and has received honoraria for educational lectures from sanofi-aventis and Merck.